Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 February 2023 | Story Valentino Ndaba | Photo UFS Photo Archive
The UFS Protest Protocol offers the university community safety guidelines during protests, including dos and don’ts for staff and students who are not demonstrating; acceptable and unacceptable behaviour during protests, and how to handle protests in accordance with standard operating procedures

The University of the Free State (UFS) recognises the right of students and staff members to peacefully assemble, picket, and protest in a way that does not interfere with the rights of other members of the university community. At the same time, the safety of all UFS staff and students is one of our top priorities.

The UFS Protest Protocol offers the university community safety guidelines during protests, including dos and don’ts for staff and students who are not demonstrating; acceptable and unacceptable behaviour during protests, and how to handle protests in accordance with standard operating procedures.

As a university, we continuously strive to create an inclusive environment where opposing views are accommodated, and the constitutional right to protest is respected. According to the UFS’s Vision 130 strategy, one of the key principles that drive the institution is social justice: “The university recognises that diversity goes together with a commitment to inclusivity, equity, and social justice. We therefore also commit to creating a culture of care and a vibrant space for, and acceptance of, constructive and critical engagement; where a diversity of often contested ideas and perspectives is not just tolerated, but also fostered through discussion and subsequent implementation.”

What should one do if a protest occurs?

1. Communicate: The university must be informed if it is to respond appropriately to protest action. If you are aware of ongoing or impending protest action, immediately inform the relevant 24/7 Protection Services operational centre.

2. Be informed: In order to respond appropriately to protest action (for your own protection and the protection of others), you need to know about impending or ongoing protests and stay informed on how it unfolds, via official UFS communication platforms and ConnectYard. The latter provides as-it-happens crisis alert notifications via WhatsApp.

3. Keep away: If at all possible, keep away from the area of the protest action. Try to keep others for whom you are responsible away as well.

4. Help others: If someone appears to be in danger or distress, intervene only if you are sure that it is safe for you to do so, and proceed calmly, without provoking protesters. Seek treatment for injuries. Should you or someone else suffer injuries of any kind during protest action, seek treatment from emergency services or Kovsie Health. Contact the Protection Services operational centres for any medical emergencies, so that they can activate the ambulance services according to available protocols.

5. Report: Report all incidents and damages to Protection Services at the numbers provided. It is important that non-protesting staff and students submit statements to the UFS investigating officers for the internal disciplinary process, to prevent similar occurrences in future. Be specific when providing a statement, to enable the investigating team to identify those involved in violent disruptions. Culprits cannot be brought to book if no evidence is available to link them to specific incidents. All reasonable steps will be taken to protect non-protesting staff and students testifying in disciplinary proceedings.

For advice on what to do and what not to do, read the UFS Protest Guidelines booklet. You can also watch the video below for more information:

 

Bloemfontein Campus
Protection Services: +27 51 401 2911 | +27 51 401 2634 | 0800 204 682
Ambulance: +27 80 005 1051 | 10177
Social worker: +27 73 182 3048
Kovsie Health: +27 51 401 2603

Qwaqwa Campus     
Protection Services: +27 58 718 5460 | +27 58 718 5175 | +27 58 718 5360
Ambulance: 10177
Social Worker: +27 58 718 5090 | +27 58 718 5091
Kovsie Health:   +27 58 718 5210                          

South Campus
Protection Services: +27 51 505 1217
Ambulance: +27 80 005 1051 | 10177
Social worker: +27 73 182 3048
Kovsie Health: +27 51 401 2603

 

 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept